PCM
BIIB icon

Prelude Capital Management’s Biogen BIIB Stock Holding History

Prelude Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$882K – 1751
2021
Q2 		$882K Buy
3,000
+2,100
+233% +$636K 0.03% 677
2021
Q1 		$252K Buy
+900
New +$243K 0.01% 1224

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Prelude Capital Management's BIIB Position: Q4 2024 in Review

Prelude Capital Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 2,400 shares — an estimated $465K sold.

Prelude Capital Management first reported a position in BIIB in Q2 2013 and held it in 38 quarters. The position peaked at $3.15M in Q1 2023. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

  • Prelude Capital Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 2,400 Biogen shares in Q4 2024, an estimated $465K.
  • Prelude Capital Management first reported a position in Biogen in Q2 2013 and held it in 38 quarters.
  • Prelude Capital Management's Biogen position peaked at $3.15M in Q1 2023.
  • 876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.